Uveitis in Behçet's disease.
The ocular complications of Behçet's disease are considered one of the major criteria upon which the diagnosis is based. Its complications are frequently sight threatening and require constant attention. The ocular disease is characterized by repeated, explosive ocular inflammatory attacks which get better by themselves, so that in-between attacks there is little or no evidence of inflammatory disease in the eye. The anterior segment can be involved alone, most frequently presenting as a severe anterior uveitis, frequently with hypopyon. This is not associated with a poor visual outcome, and usually treated with topical medication to make the patient more comfortable. However, the anterior segment disease is usually accompanied by recurrent retinal vaso-occlusive disease which is sight threatening if repeated attacks occur. Treatment is with systemic medications, including corticosteroids, cyclosporine, FK506, anti-metabolites, and cytotoxic agents. Complications of the inflammation can include retinal and optic atrophy, vitreous hemorrhage, neovascular glaucoma, and retinal detachment.
Nussenblatt
R B
RB
Laboratory of Immunology, National Eye Institute, NIH, Bethesda, MD 20892, USA.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000869:Anterior Eye Segment; D001528:Behcet Syndrome / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D002386:Cataract / Q000209:etiology / Q000628:therapy; D003078:Colchicine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D016559:Tacrolimus / Q000627:therapeutic use; D014605:Uveitis / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D014822:Vitreous Body
D000305:Adrenal Cortex Hormones; D016572:Cyclosporine; D003078:Colchicine; D016559:Tacrolimus